Hyderabad, July 29
Hetero Labs, a part of Hetero group, on Wednesday introduced the launch of generic Favipiravir in India underneath the model title ‘Favivir.’
According to a press launch issued by the city-based drug maker, Hetero has been granted the manufacturing and advertising approval for Favipiravir from the Drug Controller General of India (DCGI).
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used within the remedy of COVID-19.
It is an oral antiviral treatment that has demonstrated constructive medical outcomes.
Favivir improves remedy accessibility to a big quantity of COVID-19 affected person inhabitants, which often sustains gentle to average signs.
Hetero’s Favivir is priced at Rs 59 per pill and is marketed and distributed by Hetero Healthcare Ltd.
The product is on the market from July 29 in any respect retail medical retailers and hospital pharmacies throughout the nation and shall be offered solely on prescription, it stated.
Backed by sturdy vertical integration capabilities, the drug is being manufactured on the firm’s world-class formulation facility in India, which has been permitted by stringent international regulatory authorities akin to USFDA and the EU, amongst others, in line with the discharge. –PTI